Chester County News and Community Website
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) will be participating in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference, scheduled for October 8, 2024. This event gathers industry experts …
Arbutus Biopharma to Present at H.C. Wainwright Viral Hepatitis Virtual Conference Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in two significant investor conferences in New York.
Arbutus Biopharma to Present at Major Investor Conferences in New York Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its second quarter 2024 financial results and provided an update on its corporate strategy.
Arbutus Biopharma Reports Promising Data and Restructuring Plans in Q2 2024 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its plans to release its second quarter 2024 financial results and provide a corporate update on Thursday, August 1, 2024.
Arbutus Biopharma to Reveal Q2 Financials and Corporate Updates Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has released new data from their Phase 2a clinical trial, IM-PROVE I, revealing that imdusiran, their RNAi therapeutic, in combination with a …
Advancing Towards a Functional Cure: Promising Results in Hepatitis B Treatment Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that its management team will present and host one-on-one meetings at the Jefferies Global Healthcare Conference in New York. The formal …
Arbutus Biopharma to Present at Jefferies Global Healthcare Conference Read More
WARMINSTER, PA — Arbutus Biopharma Corporation announced that two of its research abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress …
Arbutus Biopharma to Present Key Findings at EASL Congress 2024 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) will present at two investor conferences in New York next month.
Arbutus Biopharma to Engage Investors at Upcoming New York Conferences Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the upcoming retirement of its co-founder and Chief Scientific Officer, Dr. Michael Sofia, effective December 31, 2024. Dr. Sofia, a recipient …
Arbutus Biopharma Co-Founder Dr. Michael Sofia to Retire After a Storied Career in Antiviral Drug Discovery Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has unveiled its growth during the first quarter of 2024, particularly in the development of its Hepatitis B virus (HBV) therapeutic resources. …
Arbutus Biopharma Makes Headway in Hepatitis B Treatment and Defends Intellectual Property Amidst Q1 2024 Financial Release Read More